Investigational / not FDA-approved

Cartalax

AED ultrashort peptide (CID 87815447) — ≠ Cardiogen AEDR; thin Khavinson set.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Cartalax is the ultrashort peptide alanyl-glutamyl-aspartic acid (Ala-Glu-Asp / AED) in Khavinson-line literature (often framed toward connective tissue / fibroblast / cartilage narratives). PubChem CID 87815447; formula C12H19N3O8 / MW 333.29; CAS 85806-95-7. Synonyms include H-Ala-Glu-Asp-OH / T-31 peptide. ≠ Cardiogen (AEDR) ≠ AEDL mislabeling ≠ full collagen drugs. Human confirmatory RCTs are thin or absent in this PubMed set. This drawer marks papers. It is not use advice.

Bottom line

Evidence is dominated by Khavinson-group fibroblast aging, differentiation, and ultrashort-peptide gene-expression papers. Do not grade Cartalax as a proven human osteoarthritis therapy. Keep AED (tri) separate from AEDR (Cardiogen).

Papers

Cartalax / AED / fibroblast–aging objects

PMID 27259496 — Lin'kova 2016

Tested: peptide regulation of skin fibroblast functions during aging in vitro (short-peptide panel including Cartalax-line framing).

Does not show: a human OA/cartilage repair RCT.

PMID 22808515 — Khavinson 2012

Tested: peptides tissue-specifically stimulating cell differentiation during aging (program paper spanning tissue-selective ultrashort peptides).

Does not show: pivotal human connective-tissue efficacy for Cartalax alone.

PMID 31808038 — Khavinson 2020

Tested: peptide regulation of cell differentiation (secondary synthesis including short peptides).

Does not show: a modern placebo-controlled cartilage outcome trial.

PMID 15455129 — Khavinson 2004

Tested: peptide effects promoting overcoming of the division limit in human somatic cells (gerontological cell-culture framing).

Does not show: human anti-aging clinical proof for Cartalax.

PMID 36979488 — Khavinson 2023

Tested: transporter feasibility for a panel of ultrashort peptides (includes AED-class objects among many).

Does not show: human clinical cartilage regeneration.

PMID 25946838 — Khavinson 2014

Tested: tripeptides slowing aging process in renal cell culture (related ultrashort-peptide aging narrative — keep object-tagged).

Does not show: Cartalax human joint efficacy.

What is not established

Controlled human clinical efficacy for Cartalax in osteoarthritis or tissue repair. Equivalence to Cardiogen (AEDR) or collagen biologics. That in-vitro fibroblast gene-expression changes equal consumer joint outcomes. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

27259496 22808515 31808038 15455129 36979488 25946838

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.